Stock Track | CorMedix Soars 12.60% on Strong Q3 Results and Raised 2025 Guidance

Stock Track11-12

CorMedix Inc. (CRMD) shares surged 12.60% in Wednesday's intraday trading session following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year guidance. The biopharma company's performance significantly exceeded analyst expectations, driven by strong sales of its flagship product, DefenCath.

CorMedix reported a third-quarter earnings per share (EPS) of $1.26, substantially beating the analyst consensus estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. The company's robust performance was largely attributed to DefenCath sales, which contributed $88.8 million to the quarter's net revenue of $104.3 million.

In light of the strong quarterly performance, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 million to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to between $220 million and $240 million. This optimistic outlook, coupled with the strong Q3 results, has fueled investor enthusiasm, leading to the significant stock price jump. The company's successful integration of Melinta Therapeutics, which is reportedly ahead of schedule and capturing synergies of approximately $30 million, further bolsters its growth prospects in the biopharmaceutical sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116951915?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116951915","market":"nz","top_or_hot":-1,"title":"Stock Track | CorMedix Soars 12.60% on Strong Q3 Results and Raised 2025 Guidance","media":"Stock Track","content":"<p>CorMedix Inc. (CRMD) shares surged 12.60% in Wednesday's intraday trading session following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year guidance. The biopharma company's performance significantly exceeded analyst expectations, driven by strong sales of its flagship product, DefenCath.</p>\n\n<p>CorMedix reported a third-quarter earnings per share (EPS) of $1.26, substantially beating the analyst consensus estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. The company's robust performance was largely attributed to DefenCath sales, which contributed $88.8 million to the quarter's net revenue of $104.3 million.</p>\n\n<p>In light of the strong quarterly performance, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 million to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to between $220 million and $240 million. This optimistic outlook, coupled with the strong Q3 results, has fueled investor enthusiasm, leading to the significant stock price jump. The company's successful integration of Melinta Therapeutics, which is reportedly ahead of schedule and capturing synergies of approximately $30 million, further bolsters its growth prospects in the biopharmaceutical sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CorMedix Soars 12.60% on Strong Q3 Results and Raised 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CorMedix Soars 12.60% on Strong Q3 Results and Raised 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CorMedix Inc. (CRMD) shares surged 12.60% in Wednesday's intraday trading session following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year guidance. The biopharma company's performance significantly exceeded analyst expectations, driven by strong sales of its flagship product, DefenCath.</p>\n\n<p>CorMedix reported a third-quarter earnings per share (EPS) of $1.26, substantially beating the analyst consensus estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. The company's robust performance was largely attributed to DefenCath sales, which contributed $88.8 million to the quarter's net revenue of $104.3 million.</p>\n\n<p>In light of the strong quarterly performance, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 million to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to between $220 million and $240 million. This optimistic outlook, coupled with the strong Q3 results, has fueled investor enthusiasm, leading to the significant stock price jump. The company's successful integration of Melinta Therapeutics, which is reportedly ahead of schedule and capturing synergies of approximately $30 million, further bolsters its growth prospects in the biopharmaceutical sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"","article_id":"1116951915","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116951915","pubTimestamp":1762959761,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CorMedix Inc. (CRMD) shares surged 12.60% in Wednesday's intraday trading session following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"个股追踪|CorMedix第三季度业绩强劲飙升12.60%并上调2025年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":1},"content_text":"CorMedix Inc. (CRMD) shares surged 12.60% in Wednesday's intraday trading session following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year guidance. The biopharma company's performance significantly exceeded analyst expectations, driven by strong sales of its flagship product, DefenCath.\nCorMedix reported a third-quarter earnings per share (EPS) of $1.26, substantially beating the analyst consensus estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. The company's robust performance was largely attributed to DefenCath sales, which contributed $88.8 million to the quarter's net revenue of $104.3 million.\nIn light of the strong quarterly performance, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 million to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to between $220 million and $240 million. This optimistic outlook, coupled with the strong Q3 results, has fueled investor enthusiasm, leading to the significant stock price jump. The company's successful integration of Melinta Therapeutics, which is reportedly ahead of schedule and capturing synergies of approximately $30 million, further bolsters its growth prospects in the biopharmaceutical sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116951915","isCrawlerRequest":true}